Cellular Engineering Technologies, Inc. (CET) is a biotechnology company headquartered in Coralville, Iowa, specializing in the development of optimized reagents and human cell lines to address challenges in next-generation cell therapies and regenerative medicine. Founded in 2000 by Dr. Alan Moy and Anant Kamath, CET focuses on creating scalable, efficient, and cost-effective solutions to advance cell-based research and therapeutic applications.
Product and Service Offerings:
- Human Cell Lines: CET provides a diverse array of human somatic stem cell lines and induced pluripotent stem cells (iPSCs) for research purposes. Notably, the company has developed iPSC lines using proprietary methods that are virus and oncogene-free, suitable for both adherent and suspension-based cultures.
- Cell-Specific Media Formulations: To support efficient stem cell expansion and differentiation, CET offers specialized media formulations optimized for robust cell growth and functionality.
- Human Recombinant Proteins and Cytokines: The company supplies native, human recombinant growth factors and cytokines designed to elicit maximum cellular responses and bioavailability in cell culture systems.
- Contract Research Services: CET provides contract research services tailored to the biopharmaceutical sector, focusing on applications that interface with stem cell technology
